Overview
From a portfolio lens, Injective ($490.41M) and ULTIMA ($210.39M) offer different beta to bitcoin cycles. The overview below keeps the facts first and the narrative second.
Quick winners
Full comparison
| Metric | INJ | ULTIMA |
|---|---|---|
| Price | $4.99 | $1,861.70 |
| Market Cap | $490.41M | $210.39M |
| FDV | — | — |
| Volume 24h | $2.65M | $2.42M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 155.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | ULTIMA |
|---|---|---|
| 1H | — | — |
| 24H | +1.03% | +0.70% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | ULTIMA |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.07 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 65.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Relative technical health favors reading both charts side by side. AI scores (46.90 vs 57.80) summarize PEPS modules, but supports and resistances still decide invalidation.
Fundamentals
| Metric | INJ | ULTIMA |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
ULTIMA
Pros and cons
Pros of Injective
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
Cons of Injective
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
- Indicator stacks on Injective may stay stretched longer than expected in strong trends.
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
Pros of ULTIMA
- ULTIMA can offer higher relative beta when market attention rotates toward its niche.
- PEPS tracking for ULTIMA still includes AI score and level context for monitoring.
- Active volume bursts on ULTIMA sometimes precede sharper tactical moves.
Cons of ULTIMA
- Relative underperformance versus Injective can persist through entire market regimes.
- Higher volatility on ULTIMA cuts both ways and demands stricter risk limits.
- Smaller book depth versus large caps can increase slippage for ULTIMA.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
Which looks stronger right now?
If you weight capitalization and liquidity, Injective looks sturdier; if you weight 24h tape, Injective is ahead. A balanced view treats both as incomplete signals.
AI summary
PEPS synthesizes module output into a readable pair brief. Headline stats put Injective at $4.99 and ULTIMA at $1,861.70. Relative performance over 24h (Injective) is a short window. Pair it with 30d/1y rows before inferring regime change. Return to related comparisons and individual coin intelligence pages to validate whether the relative story still holds after fresh prints.
FAQ
Which is better, Injective or ULTIMA?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or ULTIMA?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and ULTIMA.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.